Immunitybio Inc reports results for the quarter - Earnings Summary

• Immunitybio Inc IBRX.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -19 cents. The mean expectation of three analysts for the quarter was for a loss of 18 cents per share. Wall Street expected results to range from -19 cents to -17 cents per share.

• Revenue rose 7,346.3% to $6.11 million from a year ago; analysts expected $2.93 million.

• Immunitybio Inc's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $85.73 million.

• Immunitybio Inc shares had risen by 46.5% this quarter and gained 8.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 12.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunitybio Inc is $8.00

This summary was machine generated from LSEG data November 12 at 03:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)